CN102294014B - 一种促肝细胞生长素,其制剂和用途 - Google Patents
一种促肝细胞生长素,其制剂和用途 Download PDFInfo
- Publication number
- CN102294014B CN102294014B CN201110264981.7A CN201110264981A CN102294014B CN 102294014 B CN102294014 B CN 102294014B CN 201110264981 A CN201110264981 A CN 201110264981A CN 102294014 B CN102294014 B CN 102294014B
- Authority
- CN
- China
- Prior art keywords
- hepatocyte growth
- speed
- promoting factors
- refrigerated
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003494 hepatocyte Anatomy 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 239000000243 solution Substances 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000012510 hollow fiber Substances 0.000 claims abstract description 36
- 239000012528 membrane Substances 0.000 claims abstract description 35
- 238000010438 heat treatment Methods 0.000 claims abstract description 23
- 238000001914 filtration Methods 0.000 claims abstract description 19
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 210000004185 liver Anatomy 0.000 claims description 22
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 21
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 21
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 19
- 238000010792 warming Methods 0.000 claims description 17
- 238000010257 thawing Methods 0.000 claims description 16
- 239000004744 fabric Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 210000003195 fascia Anatomy 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 238000001223 reverse osmosis Methods 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 abstract description 18
- 230000008014 freezing Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 7
- 238000007789 sealing Methods 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 43
- 239000007791 liquid phase Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 229910001220 stainless steel Inorganic materials 0.000 description 16
- 239000010935 stainless steel Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000470 constituent Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000013619 trace mineral Nutrition 0.000 description 9
- 239000011573 trace mineral Substances 0.000 description 9
- 239000011575 calcium Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005524 hole trap Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- -1 levulose acid anhydride Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940087511 calcium disodium versenate Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110264981.7A CN102294014B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110264981.7A CN102294014B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102294014A CN102294014A (zh) | 2011-12-28 |
CN102294014B true CN102294014B (zh) | 2014-01-29 |
Family
ID=45354847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110264981.7A Active CN102294014B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102294014B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104313100A (zh) * | 2014-10-27 | 2015-01-28 | 合肥平光制药有限公司 | 一种超声酶解促肝细胞生长素的高效制备方法 |
CN104388510A (zh) * | 2014-10-27 | 2015-03-04 | 合肥平光制药有限公司 | 一种高提取率高活性促肝细胞生长素的制备方法 |
CN114805530B (zh) * | 2022-05-27 | 2024-03-26 | 福建农业职业技术学院 | 一种鸡肝细胞生长因子的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100417412C (zh) * | 2003-03-28 | 2008-09-10 | 威海赛洛金药业有限公司 | 促肝细胞生长素注射液及制备方法和应用 |
CN1903357B (zh) * | 2005-07-27 | 2011-09-14 | 武汉同源药业有限公司 | 注射用肝水解肽及其制备方法 |
CN1327851C (zh) * | 2005-10-12 | 2007-07-25 | 郭斌阁 | 一种促肝细胞生长蛋白质的制备工艺及其注射剂制备方法 |
CN100464735C (zh) * | 2006-08-02 | 2009-03-04 | 沈阳斯佳科技发展有限公司 | 促肝细胞生长素水针制剂的制备方法 |
CN101091722A (zh) * | 2007-06-29 | 2007-12-26 | 石海 | 肝水解肽注射液 |
-
2011
- 2011-09-08 CN CN201110264981.7A patent/CN102294014B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102294014A (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105586379B (zh) | 一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法 | |
JP4420470B2 (ja) | あわび多糖類抽出方法 | |
CN102488713B (zh) | 一种制备羊胎盘素和羊胎盘水解胶原浓缩液的方法 | |
CN108610274B (zh) | 一组环γ-聚谷氨酸系列分子及其制备方法和应用 | |
CN104151424B (zh) | 一种藻蓝蛋白的提取方法 | |
CN104232718B (zh) | 铁皮石斛抗肿瘤多肽的制备方法及应用 | |
CA2728358C (en) | Storage-stable, functionally intact fibrinogen | |
CN102294014B (zh) | 一种促肝细胞生长素,其制剂和用途 | |
CN108118077A (zh) | 一种酶法水解三文鱼胶原制备抗氧化肽与抗冻肽的工艺 | |
CN107298710A (zh) | 一种螺旋藻藻蓝蛋白的提取方法 | |
CN101020715B (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
CN102188692A (zh) | 一种骨肽组合物及其制剂、制备方法和应用 | |
CN101934068B (zh) | 胸腺肽注射液的制备方法 | |
KR101916759B1 (ko) | 고농도, 고순도의 동종 콜라겐 제조 방법 및 동종 콜라겐 지지체의 제조방법 | |
CN102294013B (zh) | 一种促肝细胞生长素,其制剂及应用 | |
CN103740797B (zh) | 一种利用高温花生粕制备高水解度功能性短肽的方法 | |
CN109395074A (zh) | 一种乙型脑炎灭活疫苗冻干制剂及其制备方法 | |
CN112028988A (zh) | 一种冻干型人凝血因子viii的制备方法 | |
CN101104847B (zh) | 圆斑蝰蛇蛇毒凝血x因子激活酶及其提取方法与应用 | |
CN104524603B (zh) | 可被生物机体吸收的止血生物制品/生物材料的病毒去除/灭活方法 | |
CN107595924B (zh) | 一种骨瓜提取物注射液制备方法及相应的药物组合物 | |
CN110551789A (zh) | 一种具有成骨活性的贻贝肽冻干粉的制备方法 | |
CN106474461B (zh) | 制备冻干人凝血酶的方法 | |
CN101081865B (zh) | 鹿茸促生长释放因子(deer ghrf)提取及其制备方法 | |
CN103041366A (zh) | 一种骨肽组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU VANKING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HOSPITAL NO.458 OF P.L.A.;HOSPITAL NO.458 OF P.L.A. Effective date: 20150522 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510600 GUANGZHOU, GUANGDONG PROVINCE TO: 510760 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150522 Address after: 510760 Guangdong city of Guangzhou Province Economic and Technological Development Zone East Road No. 6 self building Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 510600 No. 801 Dongfeng East Road, Guangdong, Guangzhou Patentee before: 458TH HOSPITAL OF PLA |
|
CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Kong Xiangping Inventor after: Chen Guangming Inventor after: Zhang Yijun Inventor after: Yang Fuqiang Inventor after: Zhang Haisong Inventor after: Chen Yangshu Inventor before: Kong Xiangping Inventor before: Chen Guangming Inventor before: Zhang Yijun Inventor before: Yang Fuqiang Inventor before: Zhang Haisong Inventor before: Chen Yangshu |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221117 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangdong 510760 Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |